Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
View Patent ↗Gene expression profiling and hierarchal clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1/Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1/Ep-CAM by monoclonal chimeric/humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas.
1. A method of detecting ovarian serous papillary carcinoma in an individual, comprising the steps of:
examining a tumor sample from said individual by the expression level of a group of genes consisting of LAMC2, CLDN4, CLDN3, TACSTD1, TFAP2A, KRT6E, CDKN2A, UGT2B7, L1CAM, TACSTD2, LAD1, KIBRA, HBP17, PAX8, CLDN7, LAMA3, S100A1, CDH6, LCN2, FOLR3, DEFB1, BIK, FGF18, LAMB3, S100A2, WNT7A, GAL, CD24, EPHAT, HDAC9, DUSP4, ERBB3, CELSR1, NMU, ANXA3, KLK10, TRIM29, SERPINB2, ITGB4, CCNA1, CDH1, IL1RN, DKK1, DSP, TNNT1, ERBB2, SPP1, BUB1B, KLK6, BMP7, TSPAN-1, IMP-3, LISCH7, HOXB2, TTK, FGFR2, TGFA, NUP210, NFE2L3, CCND1, SFN, SRCAP, CCNE1, KRT6E, MAP17, MKI67, CDC6, PRSSB, SPP1, ITPR3, UPK1B, SERPINB5, TOP2A, CA2, KRT7, PLS1, MAL, KIF11, PITX1, ARHGAP8, TRIM16, HOXB5, PKP3, CXADR, TFAP2C, FGFR3, MAPK13, ITGA3, STHM, DUSP10, RAI3, TPX2, DHCR24, MGC29643, MUC1, JUP, SLPI, CDC2; HMMR, PTPRR, LMNB1, C14orf78, CD47, C16orf34, ST14, CDKN3, MCM4, VAMP8, TNFAIP2, FOXM1, SPINT1, MKI67, UBE2C, GPR56, RAU, ZNF339, ITPR3, and EFNA1; and
performing hierarchical cluster analysis on the expression levels of said genes as compared to those in normal individual, wherein over-expression of said genes indicates that said individual has ovarian serous papillary carcinoma.
2. A method of detecting ovarian serous papillary carcinoma in an individual, comprising the steps of:
examining a tumor sample from said individual by the protein expression level of gene product in a group consisting of laminin, tumor-associated calcium signal transducer 1 (TROP-1/Ep-CAM), tumor-associated calcium signal transducer 2 (TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPINB2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin; and
performing hierarchical cluster analysis on the expression levels of said genes as compared to those in normal individual, wherein over-expression of said genes indicates that said individual has ovarian serous papillary carcinoma.
3. The method of claim 1 , wherein said gene expression is examined by DNA microarray.
4. The method of claim 1 , wherein there is at least a 5-fold over-expression of said genes.
5. The method of claim 2 , wherein said gene expression is examined by DNA microarray, flow cytometry or immunochemistry.
6. The method of claim 2 , wherein there is at least a 5-fold over-expression of said genes.